BIZARRE: Do wall street analysts like regeneron pharmaceuticals stock - You Need To See This

New York-based Regeneron Pharmaceuticals, Inc. (REGN) discovers, develops, manufactures, and commercializes medicines for treating serious medical conditions. Valued at a market cap of $81.1 billion, the company’s portfolio consists of nine marketed drugs, which are  Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. It also developed an antibody cocktail for COVID-19 called REGEN-COV.

Shares of this biotech company have significantly lagged behind the broader market over the past 52 weeks. REGN has declined 6.1% over this time frame, while the broader S&P 500 Index ($SPX) has gained 31.3%. Moreover, on a YTD basis, the stock is down 14.7%, compared to SPX’s 25.5% gain.